Screener
Eligibility screening
A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis
2 US sites in MI, PA
Before we begin
Who are you filling this out for?
Your answer affects how the questions are phrased.